These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18784314)

  • 1. Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a global Candida antifungal surveillance program.
    Pfaller MA; Boyken LB; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2008 Nov; 46(11):3585-90. PubMed ID: 18784314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of 24-hour posaconazole and voriconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: application of epidemiological cutoff values to results from a global Candida antifungal surveillance program.
    Pfaller MA; Boyken LB; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ
    J Clin Microbiol; 2011 Apr; 49(4):1274-9. PubMed ID: 21289155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of results of fluconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program.
    Pfaller MA; Hazen KC; Messer SA; Boyken L; Tendolkar S; Hollis RJ; Diekema DJ
    J Clin Microbiol; 2004 Aug; 42(8):3607-12. PubMed ID: 15297505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.
    Pfaller MA; Messer SA; Boyken L; Tendolkar S; Hollis RJ; Diekema DJ
    J Clin Microbiol; 2008 Feb; 46(2):551-9. PubMed ID: 18094129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest.
    Fleck R; Dietz A; Hof H
    J Antimicrob Chemother; 2007 Apr; 59(4):767-71. PubMed ID: 17293369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of microdilution and disk diffusion methods for the detection of fluconazole and voriconazole susceptibility against clinical Candida glabrata isolates and determination of changing susceptibility with new CLSI breakpoints].
    Hazırolan G; Sarıbaş Z; Arıkan Akdağlı S
    Mikrobiyol Bul; 2016 Jul; 50(3):428-37. PubMed ID: 27525398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values.
    Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
    Diagn Microbiol Infect Dis; 2013 Sep; 77(1):37-40. PubMed ID: 23870164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Disk diffusion method for fluconazole susceptibility testing of Candida spp. isolates].
    Rodero L; Córdoba S; Vivot W; Campo M; Corfield P; Olguín C; Cuirolo A; Soria M; Guelfand L; Canteros CE; Davel G;
    Rev Argent Microbiol; 2006; 38(3):155-63. PubMed ID: 17152217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regression analysis and categorical agreement of fluconazole disk zone diameters and minimum inhibitory concentration by broth microdilution of clinical isolates of Candida.
    Aggarwal P; Kashyap B
    J Mycol Med; 2017 Jun; 27(2):220-226. PubMed ID: 28363817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program.
    Pfaller MA; Boyken L; Hollis RJ; Kroeger J; Messer SA; Tendolkar S; Diekema DJ;
    Diagn Microbiol Infect Dis; 2009 Sep; 65(1):27-34. PubMed ID: 19679232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program.
    Pfaller MA; Boyken L; Messer SA; Tendolkar S; Hollis RJ; Diekema DJ
    J Clin Microbiol; 2005 Oct; 43(10):5208-13. PubMed ID: 16207985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study.
    Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Fothergill A; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
    J Clin Microbiol; 2005 Sep; 43(9):4535-40. PubMed ID: 16145103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of the VITEK 2 system (AST-YSO1 cards) for antifungal susceptibility testing against different Candida species].
    Ochiuzzi ME; Arechavala A; Guelfand L; Maldonado I; Soloaga R;
    Rev Argent Microbiol; 2014; 46(2):111-8. PubMed ID: 25011594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter evaluation of the new Vitek 2 yeast susceptibility test using new CLSI clinical breakpoints for fluconazole.
    Pfaller MA; Diekema DJ; Procop GW; Wiederhold NP
    J Clin Microbiol; 2014 Jun; 52(6):2126-30. PubMed ID: 24719450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.
    Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE
    J Clin Microbiol; 2005 Aug; 43(8):3884-9. PubMed ID: 16081926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp.
    Pfaller MA; Diekema DJ; Procop GW; Rinaldi MG
    J Clin Microbiol; 2007 Mar; 45(3):796-802. PubMed ID: 17215344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison of Clinical Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution methods for determining the susceptibilities of Candida isolates].
    Dalyan Cilo B; Topaç T; Ağca H; Sağlam S; Efe K; Ener B
    Mikrobiyol Bul; 2018 Jan; 52(1):35-48. PubMed ID: 29642828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CHROMagar Candida medium for direct susceptibility testing of yeast from blood cultures.
    Tan GL; Peterson EM
    J Clin Microbiol; 2005 Apr; 43(4):1727-31. PubMed ID: 15814992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].
    Karabıçak N; Alem N
    Mikrobiyol Bul; 2016 Jan; 50(1):122-32. PubMed ID: 27058336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.